initi hold pt stock
posit continu solid top bottom-lin growth
initi coverag zoeti hold rate
pt despit hold rate stock view best-in-class
anim health compani attract combin sustain organ
growth diversifi portfolio low-risk strategi cash-pay model
leverag infrastructur expect base busi drive solid revenu
earn growth next year may supplement
select busi develop new launch said believ
attribut larg understood marketplac would
prefer attract entri point click initi note
global leader attract anim health market
largest anim health compani world well-
diversifi portfolio geograph across companion anim
food anim diagnost segment sinc spun pfizer
nr establish strong track record above-market
revenu growth margin expans
anim health market rel consist grower
expect continu base popul growth rise pet ownership
spend increas demand protein histor grown revenu
faster overal market expect trend continu
hyper growth driven derm franchis like moder
experienc particularli robust growth companion anim busi
driven success novel dermatolog product apoquel
jak inhibitor cytopoint atop dermat dog
model slow growth product compound-annual-growth-rate vs
account potenti competit like materi
time develop new monoclon antibodi chronic pain dog
cat well dermatolog indic cat could import
strong balanc sheet support capit deploy
solid balanc sheet net debt/ebitda cash flow
buyback modest grow dividend yield growth
tr target
valuat risk
pt assum stock trade ebitda repres modest
discount current ev/ebitda multipl downsid risk includ lower growth
livestock companion segment lower growth abaxi lower sale key product
apoquel cytopoint consolid custom and/or competitor global econom downturn
advers fx trend upsid risk includ higher growth livestock companion abaxi
higher sale apoquel cytopoint greater contribut new product
page
zoeti largest anim health compani world sale compani strong
perform sinc spun consist above-market revenu growth
signific margin expans well-diversifi revenu base geograph across
companion food anim segment compani expand veterinari diagnost market
acquisit abaxi
model assumpt valuat
target price assum stock trade ebitda
ep repres modest discount current ev/ebitda price-to-earnings multipl
respect refer stock histor trade averag multipl
forward next month ebitda ep respect
mean median high low base data
mean median high low base data
also assess valuat use dcf model model sale period determin
termin valu base termin growth rate model assumpt includ
us livestock sale grow compound-annual-growth-rate us companion sale grow
compound-annual-growth-rate us companion sale reflect moder growth apoquel cytopoint
compound-annual-growth-rate vs account potenti competit
page
intern livestock sale grow compound-annual-growth-rate intern companion
sale grow compound-annual-growth-rate
abaxi sale grow compound-annual-growth-rate believ grow outperform growth
overal diagnost market time
sg continu grow rate revenu consist ztss strategi
assum termin growth rate given growth durabl natur anim
health busi discount after-tax profit back end believ
approxim compani weight averag cost capit
dcf analysi yield theoret valu
figur summar estim figur summar dcf analysi
page
changetot revenuegross zoeti inc
companion sale grow
companion sale grow
companion sale grow
compound-annual-growth-rate
livestock sale grow
compound-annual-growth-rate
abaxi sale grow
compound-annual-growth-rate
compound-annual-growth-rate
compound-annual-growth-rate
livestock sale grow
compound-annual-growth-rate
abaxi sale grow
compound-annual-growth-rate
livestock sale grow
cagr
abaxi sale grow
compound-annual-growth-rate
page
zoeti inc
page
potenti launchestimingcommentsinject product protect dog heartworm seek fda approv inject product protect dog heartworm month approv launch possibl apoquel atop dermat dog plan launch apoquel china simparica trio parasiticid flea tick combin parasiticid compos simparica two activ ingredi review us europ protect dog flea tick heartworm expect launch simparica trio believ product blockbust potenti potenti mileston eventstimingcommentscomplet construct vaccin manufactur facil expect complet construct vaccin manufactur facil china end potenti competit apoquel cytopoint experienc particularli robust growth companion anim busi driven success novel dermatolog product apoquel jak inhibitor cytopoint atop dermat dog competit could materi point zoeti inc
page
expens attribut non-control zoeti inc
page
expens attribut non-control zoeti inc
page
changeu oper revenueu zoeti inc
page
changeu oper revenueu zoeti inc
statement balanc sheet
page
flow statementgaap net oper work provid oper purchas proce sale invest activ use invest from/ repay common net financ activ use financ exchange-r chang equival decreas increas equival end sheetcash cash current current non-current current current non-current stockhold liabil stockhold zoeti inc
statement balanc sheet cont
page
analysistot flow cash zoeti inc
zoeti largest anim health compani world sale compani strong
perform sinc spun consist above-market revenu growth
signific margin expans well-diversifi revenu base geograph across
companion food anim segment compani expand veterinari diagnost
market acquisit abaxi
despit hold rate stock view best-in-class anim health compani
attract combin sustain organ growth diversifi portfolio low-risk strategi
cash-pay model leverag infrastructur expect base busi drive solid revenu
earn growth next year may supplement select busi
develop new launch said believ attribut larg understood
marketplac would prefer attract entri point thu rate share hold
valuat risk
pt assum stock trade ebitda repres modest
discount current ev/ebitda multipl downsid risk includ lower growth
livestock companion segment lower growth abaxi lower sale key product
apoquel cytopoint consolid custom and/or competitor global econom downturn
advers fx trend upsid risk includ higher growth livestock companion abaxi
higher sale apoquel cytopoint greater contribut new product
compani mention note
inc rate
gregg gilbert herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
